Fasting Bioequivalence Study of Memantinol 20 mg Tablets Versus Akatinol Memantine® 20 mg Tablets In Normal Healthy Subjects

Bioequivalence, AUC, Cmax, Pharmacokinetics Clinical Trial

Official title:

A Two-way Crossover, Open-label, Single-dose, Fasting, Bioequivalence Study of Memantinol® (JSC "GEROPHARM", Russia) 20 mg Tablets Versus Akatinol Memantine® (Merz Pharma GmbH & Co. KGaA, Germany) 20 mg Tablets in Normal Healthy Subjects

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03121820
• Other study ID #: BIOMEM-20
• Status: Completed
• Phase: Phase 1
• Start date: October 11, 2016
• Est. completion date: November 19, 2016

Study information

• Verified date: July 2017
• Source: Geropharm
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study are two-way crossover, open-label, single-dose, fasting, bioequivalence study of Memantinol® (JSC "GEROPHARM", Russia) 20 mg tablets versus Akatinol Memantine® (Merz Pharma GmbH & Co. KGaA, Germany) 20 mg tablets in normal healthy subjects

Description:

Study to evaluate the bioequivalence of orally administered memantinol preparations, film-coated tablets, 20 mg

Recruitment information / eligibility

• Status: Completed
• Enrollment: 18
• Est. completion date: November 19, 2016
• Est. primary completion date: November 19, 2016
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

• Signed informed consent form.

• Healthy male and female subjects aged 18 to 45 years.

• Verified diagnosis is "healthy" according to data Standard clinical, laboratory and Instrumental methods of examination.

• Have a body mass index between 18,5 and 27 kg/m2.

• Females must have a negative pregnancy test.

• Subjects must use, with their partner, methods of highly effective contraception; if the Hormonal contraceptives was used they must canceled have at least 2 month before the study.

from the time of IMP administration until 3 months after the last dose of IMP.

Exclusion Criteria:

• History of serious allergic problems/events

• Medicinal intolerance.

• History of allergic reactions to memantine or investigator's product components

• Any acute and chronic diseases of the cardiovascular system, cardiovascular, bronchopulmonary, neuroendocrinal systems, as well as diseases of the gastrointestinal tract, liver, kidneys, blood.

• Acute infectious diseases in less than 4 weeks before the start of the study.

• Subjects who have taken medication 4 weeks preceding before the study.

• Subjects who have taken any drugs known effects on hemodynamics or to induce or inhibit hepatic drug metabolism within 30 days prior to administration of the study medication (examples of inducers: barbiturates, omeprazole, etc.).

• Donation of plasma (450 mL or more) within 2 month prior to administration of the study medication.

• History of significant alcohol or drugs abuse or any indication of the regular use of more than 10 units of alcohol per week (1 Unit = 200 mL of wine or 500 mL of beer or 50 mL of alcohol 40%).

• Smokers.

• Participation in other clinical training is less than than for 3 months before the study.

• Lack of signed informed consent form.

• ECG or vital signs abnormalities (clinically significant).

• Positive testing for alcohol, drugs, pregnancy.

Related Conditions & MeSH terms

• Bioequivalence, AUC, Cmax, Pharmacokinetics

Intervention

Drug:
• Memantinol tablets, 20 mg
Bioequivalence Memantine Hydrochloride (JSC "GEROPHARM", Russia) 20 mg film-coated tablets fasting condition
• Akatinol Memantine® tablets, 20 mg
Bioequivalence Memantine Hydrochloride (Merz Pharma GmbH & Co. KGaA, Germany) 20 mg film-coated tablets fasting condition

Locations

Country	Name	City	State
Russian Federation	City Clinical Hospital ? 15 named. O.M.filatova	Moscow

Sponsors (1)

Lead Sponsor	Collaborator
Geropharm

Country where clinical trial is conducted

Russian Federation, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Pharmacokinetics of Memantinol by Assessment of Area Under the Curve From Time Zero Extrapolated to Infinity (AUC(0-inf))	Comparison of the pharmacokinetic profile in terms of plasma concentration-time curve from time zero extrapolated to infinity, AUC(0-inf), of memantinol sourced in Memantinol® (JSC "GEROPHARM", Russia) and Akatinol Memantine® (Merz Pharma GmbH & Co. KGaA, Germany)	0 hours (pre-dose), as well as at 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 9, 10, 12, 16, 24, 36, 48 and 72 hours post-dose
Primary	Pharmacokinetics of Memantinol by Assessment of Observed Maximum Plasma Concentration (Cmax)	Comparison of the pharmacokinetic profile in terms of observed maximum plasma concentration, taken directly from the individual concentration-time curve, Cmax, of memantinol sourced in Memantinol® (JSC "GEROPHARM", Russia) and Akatinol Memantine® (Merz Pharma GmbH & Co. KGaA, Germany)	0 hours (pre-dose), as well as at 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 9, 10, 12, 16, 24, 36, 48 and 72 hours post-dose